缺失的临床试验数据:潜在COVID-19药物原始数据的证据缺口
该研究通过快速审查ClinicalTrials.gov和学术出版物,分析19种潜在COVID-19治疗药物相关临床试验的结果发布情况。在3754项已完成试验中,40.4%未在注册中心或学术文献中发布结果。羟氯喹、法匹拉韦和洛匹那韦等关键药物存在显著结果缺失,造成安全性证据缺口。
要点
- 40.4%的已完成试验未发布结果,造成COVID-19药物安全性证据缺口
- 羟氯喹、法匹拉韦和洛匹那韦的未报告试验分别占37.0%、77.8%和40.5%
- 建议对非重症疾病的实验性药物使用保持谨慎,并敦促申办方回溯报告结果
核心结论
- 存在重要的证据缺口,涉及正在被重新用于COVID-19治疗的药物的安全性数据。
- 这种不确定性可能在大流行期间导致不必要的额外发病率和死亡率。
研究设计与样本
- 对ClinicalTrials.gov上19种潜在COVID-19治疗药物的相关临床试验进行快速审查。
- 共纳入3754项已完成试验,检查结果发布情况及是否在主要完成日期后395天内及时报告。
- 同时检索PubMed和Google Scholar以识别未在注册中心列出的结果出版物。
- 对10%的试验进行第二次盲法检索以评估审查者一致性。
主要发现
- 3754项已完成试验中,1516项(40.4%)未在ClinicalTrials.gov或学术文献中发布结果。
- 1172项(31.2%)已完成试验在ClinicalTrials.gov上有表格结果。
- 1066项(28.4%)在学术文献中发表了结果,但未在ClinicalTrials.gov上报告。
- 羟氯喹相关试验中37.0%未报告,法匹拉韦77.8%未报告,洛匹那韦40.5%未报告。
临床怎么用
- 对非重症疾病使用实验性药物应保持谨慎。
- 敦促临床试验申办方回溯报告缺失的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several drugs are being repurposed for the treatment of the coronavirus disease 2019 (COVID-19) pandemic based on in vitro or early clinical findings. As these drugs are being used in varied regimens and dosages, it is important to enable synthesis of existing safety data from clinical trials. However, availability of safety information is limited by a lack of timely reporting of overall clinical trial results on public registries or through academic publication. We aimed to analyse the evidence gap in this data by conducting a rapid review of results posting on ClinicalTrials.gov and in academic publications to quantify the number of trials missing results for drugs potentially being repurposed for COVID-19. METHODS: ClinicalTrials.gov was searched for 19 drugs that have been identified as potential treatments for COVID-19. Relevant clinical trials for any prior indication were listed by identifier (NCT number) and checked for results and for timely result reporting (within 395 days of the primary completion date). Additionally, PubMed and Google Scholar were searched to identify publications of results not listed on the registry. A second, blinded search of 10% of trials was conducted to assess reviewer concordance. RESULTS: Of 3754 completed trials, 1516 (40.4%) did not post results on ClinicalTrials.gov or in the academic literature. Tabular results were available on ClinicalTrials.gov for 1172 (31.2%) completed trials. A further 1066 (28.4%) had published results in the academic literature, but did not report results on ClinicalTrials.gov . Key drugs missing clinical trial results include hydroxychloroquine (37.0% completed trials unreported), favipiravir (77.8%) and lopinavir (40.5%). CONCLUSIONS: There is an important evidence gap for the safety of drugs being repurposed for COVID-19. This uncertainty could cause unnecessary additional morbidity and mortality during the pandemic. We recommend caution in experimental drug use for non-severe disease and urge clinical trial sponsors to report missing results retrospectively.
引用
- Rodgers F, Pepperrell T, Keestra S, et al. Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs. Trials. 2021. PMID: 33451350. doi:10.1186/s13063-021-05024-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。